These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11669406)

  • 1. CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload.
    Masson S; Chimenti S; Salio M; Torri M; Limana F; Bernasconi R; Calvillo L; Santambrogio D; Gagliano N; Arosio B; Annoni G; Razzetti R; Bongrani S; Latini R
    Cardiovasc Drugs Ther; 2001 Mar; 15(2):131-8. PubMed ID: 11669406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.
    Masson S; Masseroli M; Fiordaliso F; Calvillo L; D'Aquila S; Bernasconi R; Garrido G; Torri M; Razzetti R; Bongrani S; Latini R
    J Cardiovasc Pharmacol; 1999 Sep; 34(3):321-6. PubMed ID: 10470987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion.
    Latini R; Masson S; Jeremic G; Luvarà G; Fiordaliso F; Calvillo L; Bernasconi R; Torri M; Rondelli I; Razzetti R; Bongrani S
    J Cardiovasc Pharmacol; 1998 Apr; 31(4):601-8. PubMed ID: 9554811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the alpha2-adrenergic/DA2-dopaminergic agonist CHF-1024 in preventing ventricular arrhythmogenesis and myocyte electrical remodeling, in a rat model of pressure-overload cardiac hypertrophy.
    Berni R; Cacciani F; Zaniboni M; Savi M; Bocchi L; Lapucci S; Razzetti R; Pastore F; Musso E; Stilli D
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):295-302. PubMed ID: 16495769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
    Sato T; Yoshimura R; Kawada T; Shishido T; Miyano H; Sugimachi M; Sunagawa K
    J Card Fail; 1998 Jun; 4(2):139-44. PubMed ID: 9730108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation.
    Plante E; Gaudreau M; Lachance D; Drolet MC; Roussel E; Gauthier C; Lapointe E; Arsenault M; Couet J
    Can J Physiol Pharmacol; 2004 Mar; 82(3):191-9. PubMed ID: 15052285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
    Luo JD; Zhang WW; Zhang GP; Guan JX; Chen X
    Clin Exp Pharmacol Physiol; 1999 Nov; 26(11):903-8. PubMed ID: 10561812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    de Resende MM; Kriegel AJ; Greene AS
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):265-73. PubMed ID: 17204904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats.
    Laycock SK; Kane KA; McMurray J; Parratt JR
    J Cardiovasc Pharmacol; 1996 May; 27(5):667-72. PubMed ID: 8859936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart remodeling in the hereditary hypertriglyceridemic rat: effect of captopril and nitric oxide deficiency.
    Simko F; Luptak I; Matuskova J; Babal P; Pechanova O; Bernatova I; Hulin I
    Ann N Y Acad Sci; 2002 Jun; 967():454-62. PubMed ID: 12079874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
    Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.
    Kyriakidis M; Triposkiadis F; Dernellis J; Androulakis AE; Mellas P; Kelepeshis GA; Gialafos JE
    Circulation; 1998 Apr; 97(14):1342-7. PubMed ID: 9577944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.
    Flesch M; Schiffer F; Zolk O; Pinto Y; Stasch JP; Knorr A; Ettelbrück S; Böhm M
    J Hypertens; 1997 Sep; 15(9):1001-9. PubMed ID: 9321748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
    J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
    Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
    J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of adrenergic receptors during left ventricular hypertrophy development and after regression by captopril.
    Martínez ML; Fernández-Tomé P; López-Miranda V; Colado MI; Delgado C
    J Cardiovasc Pharmacol; 1999 Oct; 34(4):505-11. PubMed ID: 10511124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure.
    Shannon RP; Friedrich S; Mathier M; Knight DR
    Cardiovasc Res; 1997 Jun; 34(3):464-72. PubMed ID: 9231029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction.
    Reddy DS; Singh M; Ghosh S; Ganguly NK
    Mol Cell Biochem; 1996 Feb; 155(1):1-11. PubMed ID: 8717433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.